In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing patients with diabetes and the value of utilizing the services of a...
In a recent retrospective cohort study, researchers examined changes in the medication regimens of patients with type 2 diabetes following the initiation of second-line therapy.
Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.
In this COVID-19 roundup, the CDC reports a record low number of COVID-19 hospitalizations, metformin reduces the likelihood of SARS-CoV-2 Viral load and rebound, remdesivir reduces mortality in older...
A team of researchers sought to establish the association between patients with diabetic retinopathy and quality of life, including vision-related quality of life.
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
Researchers examined the accuracy and viability of automated machine learning models for identifying diabetic retinopathy progression from the use of ultra-widefield retinal images.
This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...
Carol Wysham, MD, Hope Warshaw, MMSc, RD, CDCES, BC-ADM, Eugene E. Wright, Jr., MD
Carol Wysham, MD, Hope Warshaw, ...
In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing people with diabetes, the importance of diabetes self-care and...
Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.
